Novo Holdings participates in EUR 30 million Series A financing of Bactolife, a Danish biotech company dedicated to strengthening the gut microbiome and fighting antimicrobial resistance
Novo Holdings today announced it has participated in the EUR 30 million Series A Financing of Bactolife. ATHOS led the round, with participation from the Bill & Melinda Gates Foundation, Novo Holdings and other existing investors.
Bactolife is a Danish bioindustrial company developing proprietary Binding Proteins™, which strengthen the gut microbiome of humans and animals with the aim of reducing the burden of gastrointestinal infections and anti-microbial resistance.
Aleks Engel, Partner, Novo Holdings, said: “The successful Series A is another validation of Bactolife’s impressive achievements and opportunity for the future. Bactolife is a great example of the strong Danish biotech ecosystem, as its technology platform originates from a Danish University, and was then further enabled by pioneering Danish biotech companies and talents. This bodes well for the future of not only Bactolife, but the Danish biotech sector as a whole. Further, I am very pleased that the international investors share our enthusiasm for finding solutions to the global AMR crisis. Combatting antimicrobial resistance requires all hands on deck.”
